Skip to content

Repotrectinib Clinical Trial Assay (CTA)

by Almac Diagnostic Services Limited Liability Company EUDAMED

Active European Union

Ref Repotrectinib CTA

Regulatory status

as of 26 Oct 2026

RegionAuthorizationNumberDateStatus
European UnionCE/IVDD NumberB-RepotrectinibCTAPA Basic UDI-DIDate30 Jun 2022RegisteredStatusActive

Coverage

1 jurisdiction

SwedenFinlandFinlandSwedenFinlandFinlandSwedenSwedenLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyGermanyPolandPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaPolandFranceFranceAustriaHungaryRomaniaFranceFranceSloveniaBulgariaPortugalSpainSpainItalySpainSpainCroatiaGreeceMaltaCyprus
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not known
  • Not covered

European Union — CE/IVDD Expiring

Certificates: none listed in EUDAMED

Specification

EUDAMED

Device Name
Repotrectinib Clinical Trial Assay (CTA)
Model / Reference
Repotrectinib CTA
Primary DI / UDI-DI
D-RepotrectinibCTAPA
Basic UDI-DI
B-RepotrectinibCTAPA
EMDN Code
W010699 Genetic tests - other
Device Class
Class IVD General
Market of Registration
Netherlands

Manufacturer details

EUDAMED SRN
US-MF-000025491
Authorised representative
Almac Diagnostic Services Ireland Limited IE-AR-000024248

Other devices from Almac Diagnostic Services Limited Liability Company

Properties

Show properties
  • Human Tissues
  • Reagent
  • Professional Testing
  • Surgical Instrument
Other properties (6)
  • Sterile: No
  • Animal Tissues: No
  • Microbial Substances: No
  • Self Testing: No
  • Near-Patient Testing: No
  • Companion Diagnostics: No